temozolomide has been researched along with Pituitary ACTH Hypersecretion in 11 studies
Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 7.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| " Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients." | 5.01 | Advances in the medical treatment of Cushing's syndrome. ( Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R, 2019) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas." | 4.86 | Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ( Altavilla, G; Cannavò, S; Curtò, L; Ferraù, F; Granata, F; Hofland, LJ; Longo, M; Pitini, V; Torre, ML; Trimarchi, F, 2010) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 3.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia." | 2.72 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. ( Fukuoka, H; Nakao, T; Ogawa, W; Yamamoto, M, 2021) |
| "Medical therapy for Cushing disease is primarily used to control hypercortisolism in patients whose disease persists or with recurrent disease after pituitary surgery, including those awaiting the salutary effects of radiation therapy." | 2.61 | Medical Management of Cushing Disease. ( Biller, BMK; Tritos, NA, 2019) |
| "Aggressive pituitary tumours causing Cushing's Disease are very rare, difficult to treat, and usually resistant to conventional therapy." | 2.58 | Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review. ( Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Kluczyński, Ł; Pach, D; Pantofliński, J; Sokołowski, G; Sowa-Staszczak, A; Turek-Jabrocka, R; Wilusz, M; Zieliński, G, 2018) |
| "A 54-year-old man was diagnosed with Cushing's disease five years earlier on the basis of a typical clinical picture and hormonal tests." | 1.43 | Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment. ( Denew, P; Kurowska, M; Maksymowicz, M; Malicka, J; Tarach, JS; Zieliński, G, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Tritos, NA | 1 |
| Biller, BMK | 1 |
| Yamamoto, M | 2 |
| Nakao, T | 1 |
| Ogawa, W | 1 |
| Fukuoka, H | 1 |
| Gilis-Januszewska, A | 1 |
| Wilusz, M | 1 |
| Pantofliński, J | 1 |
| Turek-Jabrocka, R | 1 |
| Sokołowski, G | 1 |
| Sowa-Staszczak, A | 1 |
| Kluczyński, Ł | 1 |
| Pach, D | 1 |
| Zieliński, G | 2 |
| Hubalewska-Dydejczyk, A | 1 |
| Feelders, RA | 1 |
| Newell-Price, J | 1 |
| Pivonello, R | 1 |
| Nieman, LK | 1 |
| Hofland, LJ | 2 |
| Lacroix, A | 1 |
| Tanaka, S | 1 |
| Morita, M | 1 |
| Takeno, A | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yamada, S | 2 |
| Inoshita, N | 2 |
| Oki, Y | 1 |
| Kurosaki, M | 1 |
| Sugimoto, T | 1 |
| Zacharia, BE | 1 |
| Gulati, AP | 1 |
| Bruce, JN | 1 |
| Carminucci, AS | 1 |
| Wardlaw, SL | 1 |
| Siegelin, M | 1 |
| Remotti, H | 1 |
| Lignelli, A | 1 |
| Fine, RL | 1 |
| Bruno, OD | 1 |
| Juárez-Allen, L | 1 |
| Christiansen, SB | 1 |
| Danilowicz, K | 1 |
| Kurowska, M | 1 |
| Tarach, JS | 1 |
| Malicka, J | 1 |
| Maksymowicz, M | 1 |
| Denew, P | 1 |
| Takeshita, A | 1 |
| Taguchi, M | 1 |
| Okuda, C | 1 |
| Fukuhara, N | 1 |
| Oyama, K | 1 |
| Ohashi, K | 1 |
| Sano, T | 1 |
| Takeuchi, Y | 1 |
| Dobson, M | 1 |
| Del Porto, L | 1 |
| Maartens, NF | 1 |
| Curtò, L | 1 |
| Torre, ML | 1 |
| Ferraù, F | 1 |
| Pitini, V | 1 |
| Altavilla, G | 1 |
| Granata, F | 1 |
| Longo, M | 1 |
| Trimarchi, F | 1 |
| Cannavò, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for temozolomide and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Medical Management of Cushing Disease.
Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; S | 2019 |
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Carcinoma; Dopamine Agonists | 2021 |
Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Out | 2018 |
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodi | 2019 |
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; | 2010 |
6 other studies available for temozolomide and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Combined Modality Therapy; D | 2019 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ca | 2014 |
Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Fe | 2015 |
Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Dacarbazine; Humans; Male; Middle Aged; Pituitary ACTH Hy | 2016 |
High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine | 2009 |
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Topics: Adenoma; Clinical Trials as Topic; Dacarbazine; Humans; Pituitary ACTH Hypersecretion; Pituitary Neo | 2010 |